Erianin suppresses prostate cancer progression and attenuates STAT3 signaling
4 affiliations
- 1The Fifth Clinical Medical College, Henan University of Chinese Medicine
- 2College of Pharmacy, Henan University of Chinese Medicine
- 3Collaborative Innovation Center of Research and Development on the Whole Industry Chain for Yu-Yao in Henan Province, Henan University of Chinese Medicine
- 4Academy of Chinese Medical Sciences, Henan University of Chinese Medicine
Abstract
Background: Prostate cancer is one of the most prevalent malignancies in men, but current therapeutic strategies are often limited by suboptimal efficacy and the emergence of drug resistance.
Methods: Cell proliferation, migration, and invasion were assessed using CCK-8, colony formation, wound healing, and Transwell assays in PC-3, 22RV1, and RM-1 cells. Network pharmacology and molecular docking were used to identify candidate targets, and the effects of erianin on target were subsequently examined by western blot analysis. In vivo antitumor activity was evaluated in C57BL/6N mice bearing RM-1 tumors. Liver and kidney functions were assessed using biochemical kits, and histopathological changes in major organs were examined by H&E staining.
Results: Among the 48 compounds screened, erianin showed the most potent anti-prostate cancer activity. Further assays showed that erianin reduced colony formation, wound closure, and Transwell invaded-cell counts. In vivo , erianin markedly suppressed tumor growth, with the 20 mg/kg dose exhibiting the strongest effect. Network pharmacology and molecular docking predicted STAT3 as a candidate target of erianin, while further analysis indicated that erianin inhibited STAT3 phosphorylation and downregulated its downstream effectors including c-Myc and MMP-9. Safety evaluation revealed that erianin caused only a mild elevation in serum alanine aminotransferase (ALT) without significant histopathological alterations in major organs.
Conclusions: These findings demonstrate that erianin exerts potent anti-prostate cancer activity and that these effects are accompanied by reduced STAT3 signaling. Further functional and target-engagement studies are required to determine whether STAT3 inhibition is necessary for erianin.
Related
- JARID2 promotes prostate cancer progression associated with TET3-mediated activation of the FAK/PI3K/AKT signaling pathway
- Ligustroside attenuates fibrosis-associated wound remodeling and suppresses fibrosis-related signaling in a rat excisional wound model
- Benzoylaconine suppresses colorectal cancer progression by modulating the CDK2/MMP2 signaling axis
- Magnesium cantharidate suppresses hepatocellular carcinoma progression and modulates tumor-associated macrophage polarization: potential involvement of ERK1/2 signaling and de novo serine synthesis
- TRPML1 inhibitor ML-SI1 suppresses prostate cancer through dual regulation of androgen receptor and polyamine metabolism
BibTeX
@article{yue2026erianin,
title = {{Erianin suppresses prostate cancer progression and attenuates STAT3 signaling}},
author = {Zhouli Yue and Yufang Zhao and Jiahui Wang and Feifei Wang and Menglin Wang and Zibo Li and Yucheng Li and Min Li},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1975408},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1975408/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Erianin suppresses prostate cancer progression and attenuates STAT3 signaling
AU - Zhouli Yue
AU - Yufang Zhao
AU - Jiahui Wang
AU - Feifei Wang
AU - Menglin Wang
AU - Zibo Li
AU - Yucheng Li
AU - Min Li
PY - 2026
DA - 2026/10/21
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1975408
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1975408/full
AB - Background: Prostate cancer is one of the most prevalent malignancies in men, but current therapeutic strategies are often limited by suboptimal efficacy and the emergence of drug resistance. Methods: Cell proliferation, migration, and invasion were assessed using CCK-8, colony formation, wound healing, and Transwell assays in PC-3, 22RV1, and RM-1 cells. Network pharmacology and molecular docking were used to identify candidate targets, and the effects of erianin on target were subsequently examined by western blot analysis. In vivo antitumor activity was evaluated in C57BL/6N mice bearing RM-1 tumors. Liver and kidney functions were assessed using biochemical kits, and histopathological changes in major organs were examined by H&E staining. Results: Among the 48 compounds screened, erianin showed the most potent anti-prostate cancer activity. Further assays showed that erianin reduced colony formation, wound closure, and Transwell invaded-cell counts. In vivo , erianin markedly suppressed tumor growth, with the 20 mg/kg dose exhibiting the strongest effect. Network pharmacology and molecular docking predicted STAT3 as a candidate target of erianin, while further analysis indicated that erianin inhibited STAT3 phosphorylation and downregulated its downstream effectors including c-Myc and MMP-9. Safety evaluation revealed that erianin caused only a mild elevation in serum alanine aminotransferase (ALT) without significant histopathological alterations in major organs. Conclusions: These findings demonstrate that erianin exerts potent anti-prostate cancer activity and that these effects are accompanied by reduced STAT3 signaling. Further functional and target-engagement studies are required to determine whether STAT3 inhibition is necessary for erianin.
SN - 2234-943X
ER -